E-News - May 2023
Annual Scientific Meetings
Alliance NCTN/NCORP/AFT at 2023 ASCO
The 59th Annual Meeting of the American Society of Clinical Oncology (ASCO) will convene June 2-6, bringing together thousands of oncology professionals from around the world in person. This year's meeting theme is "Partnering with Patients: The Cornerstone of Cancer Care and Research." Studies spanning the spectrum of cancer prevention and care, from immunotherapy and precision medicine to survivorship, will be highlighted.
Each year, ASCO attendees learn from leading-edge scientific presentations, including papers and talks from Alliance researchers, as well as thousands of scientific abstracts and research news developments. At this year's conference, Alliance investigators will present more than 20 abstracts, sharing the latest findings on breast cancer, rare cancer, blood and bone cancer, GI and GU cancers, along with cancer control research. Notably, results from the Alliance N1048 (PROSPECT) trial will be highlighted at a plenary session on colorectal cancer, along with a post-hoc analysis of a metastatic breast cancer trial - CALGB (Alliance) 40502 at a clinical science symposium. The Alliance will be well-represented at this face-to-face ASCO meeting.
Take a look at studies that Alliance researchers will present:
Plenary Session: Special Session, Gastrointestinal Cancer—Colorectal and Anal
Sub Track: Colorectal Cancer - Local-Regional Disease
Alliance N1048
PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by Total Mesorectal Excision (TME) for treatment of locally advanced rectal cancer (LARC). (Alliance N1048)
Presenter: Deborah Schrag, MD
Abstract #: LBA2
The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation: Harnessing the Breast Cancer Immune Response
CALGB-40502/Alliance
Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: Post hoc analysis CALGB 40502 (Alliance)
Presenter: Daniel G. Stover, MD
Abstract #: 1010
Oral Presentations
Alliance A091902
A multicenter phase II study of cabozantinib + nivolumab for patients with advanced angiosarcoma previously treated with a taxane (Alliance A091902)
Presenter: Juneko E. Grilley Olson, MD
Abstract # 11503
Alliance A041703
Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703
Presenter: Matthew J. Wieduwilt, MD
Abstract #: 7006
Alliance A041702
Results of a phase 3 study of IVO vs IO for previously untreated older patients with CLL and impact of COVID-19 (Alliance)
Presenter: Jennifer A. Woyach, MD
Abstract #: 7500
Alliance A011401
Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial
Presenter: Jennifer A. Ligibel, MD
Abstract #: 12001
Poster Presentations
AFT-19
Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19)
Presenter: Rahul Aggarwal, MD
Abstract #: 5077 | Poster Board # 171
Alliance A231601CD
Surgical care and outcomes in older patients with cancer through implementation of a pre-surgical toolkit (OPTI-Surg): Interim results of a phase III cluster randomized trial (Alliance A231601CD)
Presenter: George J. Chang, MD
Abstract #: 1541 | Poster Board #: 135
Alliance A021806
Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer
Presenter: Akhil Chawla, MD
Abstract #: TPS4204 | Poster Board #: 508b
Alliance A032001
MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC) (Alliance A032001)
Presenter: Shilpa Gupta, MD
Abstract #: TPS4609 | Poster Board #: 97a
Alliance A022101
Alliance A022101: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer - evaluating radiation, ablation, and surgery (ERASur)
Presenter: Kathryn E. Hitchcock, MD
Abstract #: TPS3629 | Poster Board #: 326b
Alliance A031201
Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies
Presenter: Jeffrey L. Jensen, MD
Abstract #: 5021 | Poster Board #: 115
Alliance A092104
Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator’s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy
Presenter: Kristine Lacuna, MD
Abstract #: TPS11584 | Poster Board #: 515b
Alliance A092001
Phase 2 Randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001)
Presenter: Aaron Mansfield, MD
Abstract #: TPS8603 | Poster Board #: 228a
Alliance A082101
Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101)
Presenter: Aaron Mansfield, MD
Abstract #: TPS8602 | Poster Board #:227b
Alliance A022102
Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA)
Presenter: Haeseong Park, MD
Abstract #: TPS4175 | Poster Board #: 494a
Alliance N0147
Artificial intelligence-derived immune phenotypes for prediction of prognosis in patients with stage III colon cancer (NCCTG N0147; Alliance)
Presenter: Bahar Saberzadeh-Ardestani, MD
Abstract #: 3542 | Poster Board #: 242
Alliance N0147
Pathological analysis of tumor microenvironmental features using deep learning to predict survival of colon carcinomas
Presenter: Frank A. Sinicrope, MD
Abstract #: 3527 | Poster Board #: 227
Alliance A022104
Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer | The Janus Rectal Cancer Trial
Presenter: J. Joshua Smith, MD
Abstract #: TPS3640 | Poster Board #: 332a
Alliance A022004
A randomized trial of consolidation targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer (Alliance A022004)
Presenter: Rona Yaeger, MD
Abstract #: TPS3641 | Poster Board #: 332b
Alliance A021804
Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma
Presenter: Jaydira del Rivero, MD
Abstract #: TPS4191 | Poster Board #: 502a
Poster Discussions
Comprehensive
Strategies to increase accrual of underrepresented populations in Alliance NCTN trials
Presenter: Electra D. Paskett, PhD
Abstract #: 6509 | Poster Board #: 1
Alliance A051103, CALGB-50701, CALGB-50803, CALGB-50901, CALGB-50904
Impact of imaging frequency on progression free survival in Alliance clinical trials enrolling patients with untreated follicular lymphoma
Presenter: Sarah C. Rutherford, MD
Abstract #: 7520 | Poster Board #: 71
Alliance A231701CD
Impact of a web-based decision aid on socioeconomically disadvantaged patients’ engagement in decision-making (Alliance)
Presenter: Jessica R. Schumacher, PhD
Abstract #: 6520 | Poster Board #: 12
Published Only
AFT-25
From the lab to the clinic: Lessons learned from a Translational Working Group
Author: Thomas Lynch, MD
Abstract #: e12576
